Download Chemotherapy Sequencing Guide

Chemotherapy Sequencing Guide – For therapies given on the same day
ab
in
m
u
ciz
va
Be
om
l
op
rb
e
Bl
in
at
yc
Ca
e
id
m
in
lat
sp
Ci
a
ph
s
o
ph
Cy
clo
Cy
t
ar
e
zin
ne
i
ab
a
rb
ca
Da
et
c
Do
n
ici
l
e
ax
b
ru
xo
Do
n
iru
Ep
id
os
op
Et
e
da
u
Fl
b
ra
il
ac
in
e
ci
bi
or
u
Fl
r
ou
ne
bi
a
cit
m
Ge
e
id
m
sfa
Ifo
Ir
in
ot
te
al cin
xa
l
in
tin
m ubi
re
a
xe
yc
l
t
o
s or
o
p
m
i
o
ita
h
l
l
o
t
x
p
a
t
c
e
i
Li Do
M
M
Pa
Ox
rin
n
a
ec
o
ov
uc
Le
n
p
To
e
tin
ca
e
ot
is
cr
n
Vi
e
in
lb
e
or
n
Vi
B1, P2
Bleomycin
Carboplatin
Cisplatin
No Effect
F1, C2
No Effect
No Effect
F1, C2
G1, C2
T
C1, I2
E
No Effect
T1, C2
T
P1, C2
T
T1, C2
T
C1, P2
T
Cyclophosphamide
F1, C2
E
Cytarabine
D1, G2
Dacarbazine
No Effect
Docetaxel
No Effect
Doxo1,
Doce2
T
No Effect
Doxo1,
Doce2
T
Doxorubicin
D1, F2
G1, D2
No Effect
G1, D2
No Effect
Epirubicin
I1, D2
T
I1, D2
LD1, D2
T
D1, O2
P1, D2
No Effect
D1, V2
T
D1, T2
T, PK
D1, P2
T, PK
G1, E2
E1, P2
PK, T
E1, M2
Etoposide
No Effect
T1, E2
E1, V2
F1, C2
E
Fludarabine
Fluorouracil
Gemcitabine
F1, C2
F1, C2
No Effect
G1, C2
T
D1, G2
D1, F2
No Effect
G1, D2
G1, D2
G1, F2
G1,E2
I1, F2
T
G1, F2
L1, F2
E
O1, D2
G1, I2
F1, M2
E
P1, F2
G1, O2
P1, G2
E, T
I1, D2
T
Ifosfamide
I1, B2
C1, I2
E
I1, D2
I1, F2
T
L1, F2
E
P1, I2
No Effect
G1, I2
M1, L2
T
No Effect
LD1, D2
T
Liposomal
Doxorubicin
D1, O2
Oxaliplatin
O1, D2
No Effect
Methotrexate
V1, G2
P1, G2
E, T
I1, P2
Leucovorin
G1, O2
No Effect
F1, M2
E
LD1, V2
PK, T
P1, O2
M1, L2
T
E1,M2
Mitomycin
Paclitaxel
Pr
ala
te
xa
tre
I1,B2
Bevacizumab
Irinotecan
Pe
m
e
d
xe
tre
B1, P2
No Effect
P1, C2
T
C1, P2
T
D1, P2
T, PK
E1, P2
PK, T
No Effect
P1, D2
Pemetrexed
P1, G2
E, T
I1, P2
P1, I2
P1, O2
PEM1,
PAC2
P1, G2
E, T
PEM1,
PAC2
P1, G2
Pralatrexate
Topotecan
P1, F2
T1, C2
T
T1, C2
T
D1, T2
T, PK
D1, V2
T
Vinorelbine
1. Match chemotherapy agents from either the top or side columns.
3. Determine the order of “optimal sequence” as demonstrated in the
following example:
> G1, F2 = Gemcitabine given first, followed by Fluorouracil given
second.
2. First initial(s) of each agent used to explain sequence
> Example: M + methotrexate, 1 = administer first
4. Letter(s) under optimal sequence, T, E, or PK refers to an
interaction. Refer to INTERACTION LEGEND at right.
(valid only for therapies given on the same day)
No Effect
E1,V2
Vincristine
“OPTIMAL SEQUENCE” DIRECTIONS FOR USE
T1,E2
V1, G2
LD1, V2
PK, T
INTERACTION LETTERS
If a letter is present under the “optimal sequence” symbols, an interaction has been
noted in published data. Data is limited to a human, in-vivo interaction with a clear
benefit for the “optimal sequence” administration order. The letter and sequence
benefit interaction are summarized at right:
No Effect
T = a TOXICITY related interaction can be avoided
The literature supported no difference in order sequencing with respect to outcome or toxicity.
E = EFFICACY related interaction happens
X1, Y2
E
See OPTIMAL SEQUENCE directions on how to read the sequence order and Interaction letters.
PK = a PHARMACOKINETIC related interaction
X1, Y2
The literature noted no clinical effect from sequence order.
Empty Box = denotes a lack of evidence in the literature.
© October 2011 McKesson Specialty Health. All rights reserved.
References:
Adjei AA
Clinical studies of pemetrexed and gemcitabine combinations
Ann Oncol
2006;15(supp 5):v29-v32
Adjei AA, Klein CE, Kastrissios H, et al
Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: preliminary evidence
of clinical activity
JCO
2000;18:1116-1123
Koizumi W, Kurihara M, Hasegawa K, et al
Sequence dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer
Oncol Rep
2004; 12:557-561
Airoldi M, Cattel L, Passera R, et al
Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data
Pancreas
2006;32:44-50
Kroep JR, Peters GJ, van Moorsel CJ, et al
Gemcitabine cisplatin: a schedule finding study
Ann Oncol
1999;10:1503-1510
Airoldi M, Cattel L, Pedani F, et al
Clinical data and pharmacokinetics of a docetaxel vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer Acta Oncologica
2003;42:186-194
Kuroki M, Nakano S, Mitsugi K, et al
1992;29:273-276
Clinical and pharmacokinetic data of a docetaxel epirubicin combination in metastatic breast cancer
Breast Cancer Res Treat
2001;70:185-195
In vivo comparative therapeutic study of optimal administration of 5-fluorouracil and cisplatin using a newly established HST-1
human squamous-carcinoma cell line
Cancer Chemother Pharmacol
Airoldi M, Cattel L, Pedani F, et al
Airoldi M, Cattell L, Marchionatti S, et al
Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results
Am J Clin Oncology
2003;26:378-381
Langer CJ, Calvert P, Ozols RF
Gemcitabine and carboplatin in combination: phase I and phase II studies
Semin Oncol
1998;25(suppl 9):51-54
Alarcon GS, Morgan SL
Folinic acid to prevent side effects of methotrexate in juvenile rheumatoid arthritis
J Rheumatol
1996;23:2184-2185
Leu KM, Ostruszka LJ, Shewach D, et al
JCO
2004;22:1706-1712
Ando M, Saka H, Ando Y, et al
Sequence effect of docetaxel and carboplatin on toxicity, tumor response and pharmacokinetics in non-small-cell lung cancer
patients: a phase I study of two sequences
Cancer Chemother Pharmacol
2005; 55:552-558
Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the
treatment of sarcoma
Liu J, Kraut E, Bender J, et al
Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients
Cancer Chemother Pharmacol
2002;49:367-374
Belani CP, Kearns CM, Zuhowski EG, et al
Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients
with metastatic non-small-cell lung cancer
JCO
1999;17:676-684
Liu J, Kraut EH, Balcerzak S, et al
Dosing sequence dependent pharmacokinetic interaction of oxaliplatin with paclitaxel in the rat
Cancer Chemother Pharmacol
2002;50:445-453
Losa R, Fra J, Lopez-Pousa A, et al
Phase II study with the combination of gem-citabine and DTIC in patients with advanced soft tissue sarcomas
Cancer Chemother Pharmacol
2007;59:251-259
Kennedy MJ, Zahurak ML, Donehower RC, et al
Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony stimulating
factor in women with previously treated metastatic breast cancer
JCO
1996;14:783-791
Bhargava P, Marshall JL, Fried K, et al
Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancer Cancer Chemother Pharmacol
2001;48:95-103
Lunardi G, Venturini M, Vannozzi MO, et al
Influence of alternate sequences of epirubicin and docetaxel on the pharmacokinetic behavior of both drugs in advanced breast cancer
Ann Oncol
2002;13:280-285
Bonner JA, Kozelsky TF
The significance of the sequence of administration of topotecan and etoposide
Cancer Chemother Pharmacol
1996;39:109-112
Ma CX, Nair S, Thomas S, et al
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front line therapy for advanced non-small-cell lung cancer
JCO
2005;23:5929-5937
Boss DS, Siegel-Lakhai WS,
van Egmond-Schoemaker NE, et al
Phase 1 pharmacokinetic and pharmacodynamic study of carboplatin and topotecan administered intravenously every 28 days to
patients with malignant solid tumors
Clin Cancer Res
2009;15:4475-4483
Mackintosh JF, Coates AS, Tattersall MH, et al
Chemotherapy of advanced head and neck cancer: updated results of a randomized trial of the order of administration of
sequential methotrexate and 5-fluorouracil
Med Pediatr Oncol
1988;16:304-307
Cattel L, Airoldi M, Passera R, et al
Gemcitabine plus vinorelbine chemother-apy regimens: a pharmacokinetic study of alternate administration sequences
Pharm World Sci
2004;26:238-241
Mancini R, Modlin J
Chemotherapy Administration Sequence: A review if the literature and Creation of a Sequencing Chart
J Hematol Oncol Pharm
2011;1(1):17-25
Cattell L, Passera R, Katsaros D, et al
egylated liposomal doxorubicin and vinorelbine in recurrent ovarian carcinoma: a pharmacokinetic study on alternate
administration sequences
Anticancer Res
2006;26:745-750
Mans DR, Grivicich I, Peters GJ, et al
Sequence dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human
colon carcinoma cell lines
Eur J Cancer
1999;35:1851-1861
Cho H, Imada T, Oshima T, et al
In-vitro effect of a combination of 5-fluorouracil (5-FU) and cisplatin (CDDP) on human gastric cancer cell lines: timing of
cisplatin treatment
Gastric Cancer
2002;5:43-46
Markman M, Elson P, Kulp B, et al
Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment induced neutropenia
Gynecol Oncol
2003;91:118-122
Miller AA, Niell HB
Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide
Lung Cancer
2001;33:241-248
Coates AS, Tattersall MH, Swanson C, et al
Combination therapy with methotrexate and 5-fluorouracil: a prospective randomized clinical trial of order of administration
JCO
1984;2:756-761
Milross CG, Peters LJ, Hunter NR
Sequence dependent antitumor activity of paclitaxel (Taxol) and cisplatin in vivo
Int J Cancer
1995;62:599-604
Correale P, Cerretani D, Marsili S, et al
Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients
Eur J Cancer
2003;39:1547-1551
Morgan SL, Oster RA, Lee JY, et al
The effect of folic acid and folinic acid sup-plements on purine metabolism in methotrexate treated rheumatoid arthritis
Arthritis Rheum
2004;50:3104-3011
Danesi R, Conte PF, Del Tacca M
Pharmacokinetic optimisation of treatment schedules for anthracyclines and paclitaxel in patients with cancer
Clin Pharmacokinet
1999;37:195-211
Murren JR, Peccerillo K, DiStasio SA, et al
Dose escalation and pharmacokinetic study of irinotecan in combination with paclitaxel in patients with advanced cancer
Cancer Chemother Pharmacol
2000;46:43-50
de Jonge MJ, Verweij J, de Bruijn P, et al
Pharmacokinetic, metabolic, and pharmacodynamic profiles in a dose escalating study of irinotecan and cisplatin
JCO
2000;18:195-203
Obasaju CK, Johnson SW, Rogatko A, et al
Evaluation of carboplatin pharmacokinetics in the absence and presence of paclitaxel
Clin Cancer Res
1996;2:549-552
de Jonge MJ, Verweij J, Plating AS, et al
Drug administration sequence does not change pharmacodynamic and kinetics of irinotecan and cisplatin
Clin Cancer Res
1999;5:2012-2017
Oliveras-Ferraros C, Vazquez-Martin A, Colomer R, et al
Sequence dependent synergism and antagonism between paclitaxel and gemcitabine in breast cancer cells: the importance of scheduling
Int J Oncol
2008;32:113-120
Denlinger CS, Blanchard R, Xu L, et al
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors
Cancer Chemother Pharmacol
May 5, 2009
Ortiz Z, Shea B, Suarez-Almazor ME, et al
J Rheumatol
1998;25:36-43
DiPaola RS, Rubin E, Toppmeyer D, et al
Gemcitabine combined with sequential paclitaxel and carboplatin in patients with urothelial cancers and other advanced malignancies
Med Sci Monit
2003;9:PI5-PI11
The efficacy of folic acid and folinic acid in reducing methotrexate gastrointestinal toxicity in rheumatoid arthritis, a meta-analysis
of randomized controlled trials
Dumez H, Louwerens M, Pawinsky A, et al
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel
and gemcitabine in patients with advanced solid tumors
Anticancer Drugs
2002;13:583-593
Palmeri S, Trave F, Russello O, et al
The role of drug sequence in therapeutic selectivity of the combination of 5-fluorouracil and cisplatin
Sel Cancer Ther
1989;5:169-177
Pastore D, Specchia G, Carluccio P, et al
FlagIDA in the treatment of refractory relapsed acute myeloid leukemia: single center experience
Ann Hematol
2003; 82:231-235
Dupont J, Aghajanian C, Andrea G, et al
Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important?
Int J Gynecologic Cancer
2006;16(suppl 1):68-73
Perez EA, Hartmann LC
Paclitaxel and carboplatin for advanced breast cancer
Semin Oncol
1996;23(suppl 11):41-45
Edelman MJ, Quam H, Mullins B
Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines
Cancer Chemother Pharmacol
2001;48:141-144
Poole CJ, Perren T, Gawande S, et al
Int J Gynecol Cancer
2006;16:507-514
Esaki T, Nakano S, Tatsumoto T, et al
Inhibition by 5-fluorouracil of cis-diammine-dichloroplatinum(II)-induced DNA interstrand cross-link removal in a HST-1 human
squamous carcinoma cell line
Cancer Res
1992;52:6501-6506
Optimized sequence of drug administration and schedule leads to improved dose delivery for gemcitabine and paclitaxel in
combination: a phase 1 trial in patients with recurrent ovarian cancer
Posey JA, Wang H, Hamilton J, et al
Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies
Cancer Chemother Pharmacol
2005;56:182-188
Falcone A, Allegrini G, Masi G, et al
5-Fluorouracil administered as a 48-hour chronomodulated infusion in combination with leucovorin and cisplatin: a random-ized
phase II study in metastatic colorectal cancer
Oncology
2001;61:28-35
Pratesi G, Gianni L, Manzotti C, et al
Sequence dependence of the antitumor and toxic effects of 5-fluorouracil and cis-diamminedichloroplatinum combination
on primary colon tumors in mice
Cancer Chemother Pharmacol
1988;21:237-240
Falcone A, Di Paolo A, Masi G, et al
Sequence effect of irinotecan and fluo-rouracil treatment on pharmacokinetics and toxicity in chemotherapy naïve metastatic
colorectal cancer patients
JCO
2001;19:3456-3462
Pronk LC, Schellens JH, Planting AS, et al
Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors
JCO
1997;15:1071-1079
Qin B, Tanaka R, Shibata Y, et al
In-vitro schedule dependent interaction between oxaliplatin and 5-fluorouracil in human gastric cancer cell lines
Anticancer Drugs
2006;17:445-453
Felip E, Massuti B, Camps C, et al
Superiority of sequential versus concurrent administration of paclitaxel with etoposide in advanced non-small cell lung cancer:
comparison of two phase II trials
Clin Cancer Res
1998;4:2723-2728
Ramnath N, Yu J, Khushalani NI, et al
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of no small cell
lung cancer: a phase II study
Anticancer Drugs
2008;19:749-752
Fleming GF, Roth BJ, Baker SD, et al
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group Study
Am J Clin Oncology
2000;23:609-613
Ravelli A, Migliavacca D, Viola S, et al
Efficacy of folinic acid in reducing methotrexate toxicity in juvenile idiopathic arthritis
Clin Exp Rheumatol
1999;17:625-627
Focan C, Graas MP, Beauduin M, et al
Sequential administration of epirubicin and paclitaxel for advanced breast cancer, A phase I randomized trial
Anticancer Res
2005;25:1211-1217
Raymond E, Burris HA, Rowinsky EK, et al
Ann Oncol
1997;8:1003-1008
Forastiere AA, Urba SG
Single agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer
Semin Oncol
1995;22:24-27
Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously untreated
non-small-cell lung carcinoma
Fracasso PM, Rodriguez LC, Herzog TJ, et al
Phase 1 dose and sequencing study of pegylated liposomal doxorubicin and docetaxel in patients with advanced malignancies
Cancer
2003;98:610-617
Rizvi NA, Spiridonidis CH, Davis TH, et al
Docetaxel and gemcitabine combinations in non-small cell lung cancer
Semin Oncol
1999;26(suppl 16):27-31, 41-42
Frassineti GL, Zoli W, Tienghi A, et al
The sequential administration of com-bined doxorubicin and paclitaxel in the treatment of advanced breast cancer
Semin Oncol
1996;23:22-28
Rosell R, Felip E, Massuti B, et al
A sequence dependent paclitaxel-etoposide phase II trial in patients with non-small cell lung cancer
Semin Oncol
1997;24(suppl 12):56-60
Gandhi V, Kemena A, Keating MJ, et al
Fludarabine infusion potentiates arabi-nosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia
Cancer Res
1992;52:897-903
Rowinsky EK, Gilbert MR, McGuire WP, et al
Sequences of Taxol and cisplatin: a phase I and pharmacologic study
JCO
1991;9:1692-1703
Giaccone G, Huizing M, Postmus PE, et al
Dose finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer
Semin Oncol
1995;22:78-82
Rowinsky EK, Kaufmann SH, Baker SD, et al
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence
JCO
1996;14:3074-3084
Gianni L, Munzone E, Capri G, et al
Paclitaxel by 3-hour infusion in combina-tion with bolus doxorubicin in women with untreated metastatic breast cancer: high
antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
JCO
1995;13:2688-2699
Royer I, Monsarrat B, Sonnier M, et al
Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs
Cancer Res
1996;56:58-65
Rustum YM, Cao S, Zhang Z
Rationale for treatment design: biochemical modulation of 5-fluorouracil by leucovorin
Cancer J Sci Am
1998;4:12-18
Gil-Delgado MA, Bastian G, Guinet F, et al
Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients
Am J Clin Oncology
2004;27:294-298
Saikawa Y, Kubota T, Kuo TH, et al
Combined effect of 5-fluorouracil and carboplatin against human gastric cancer cell lines in vitro and in vivo
Anticancer Res
1994;14:461-464
Goel A, Grossbard ML, Malamud S, et al
Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leuco-vorin
and cisplatin in patients with metastatic pancreatic cancer
Anticancer Drugs
2007;18:263-271
Schrijvers D, Pronk L, Highley M, et al
Pharmacokinetics of ifosfamide are changed by combination with docetaxel: results of a phase I pharmacologic study
Am J Clin Oncology
2000;23:358-363
Seminara P, Pastore C, Iascone C, et al
2007;53:218-225
Randomized phase II study of two opposite administration sequences of irinotecan and cisplatin in patients with advanced
non-small cell lung carcinoma
Cancer
2006;106:873-880
Mitomycin C and etoposide in advanced colorectal carcinoma. A clinical and in vitro experience that focuses the problem
of schedule dependence in combination therapy
Chemotherapy
Han JY, Lim HS, Lee DH, et al
Simpson AB, Calvert PM, Sludden JA, et al
Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules
Ann Oncol
2002; 13:399-402
Harita S, Watanabe Y, Kiura K, et al
Influence of altering administration sequence of docetaxel, gemcitabine and cisplatin in patients with advanced non-small cell lung cancer Anticancer Res
2006;26:1637-1641
Sledge GW Jr, Robert N, Sparano JA, et al
Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer
Semin Oncol
1995;22(suppl 6):105-108
Hervonen P, Jekunen A, Lefebvre P, et al
Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone refractory prostate cancer: a phase I
pharmacokinetic study
Int J Clin Pharmacol Res
2003;23:1-7
Smorenburg CH, Sparreboom A, Bontebal M, et al
Combination chemotherapy of the taxanes and ant metabolites, use and limitations
Eur J Cancer
2001;37:2310-2323
Stanford BL, Zondor SD, Kennedy S, et al
Which One Comes First? - Development of a Chemotherapy Administration Sequence Chart.
Texas Tech Univ School of Pharmacy, Lubbock Tx
Holmes FA, Madden T, Newman RA, et al
Sequence dependent alteration of dox-orubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxoru-bicin
in patients with metastatic breast cancer
JCO
1996;14:2713-2721
Stinchcombe TE, Socinski MA, Walko CM, et al
Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment
schedules in patients with solid tumors
Cancer Chemother Pharmacol
Hotta K, Ueoka H, Kiura K, et al
A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer
Lung Cancer
2004;45:77-84
Toiyama T, Tanaka K, Konishi N, et al
Administration sequence dependent antitumor effects of paclitaxel and 5-fluorouracil in the human gastric cancer cell line MKN45
Cancer Chemother Pharmacol
2006;57:368-375
Huisman C, Postmus PE, Giaccone G, et al
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients
Ann Oncol
2001;12:1567-1573
Toner LE, Vrhovac R, Smith EA, et al
Clin Cancer Res
2006;12:924-932
Huizing MT, Giaccone G, van Warmerdam LJ, et al
Pharmacokinetics of paclitaxel and carboplatin in a dose escalating and dose sequencing study in The European Cancer Centre
patients with non-small-cell lung cancer
JCO
1997;15:317-329
The schedule dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine
in models of human Non-Hodgkin’s lymphoma
US Oncology
Chemotherapy Sequencing Chart
US Oncology
OPS.0100.B.1110
Itoh K, Sasak Y, Fujii H, et al
Study of dose escalation and sequence switching of administration of the combination of docetaxel and doxorubicin in
advanced breast cancer
Clin Cancer Res
2000;6:4082-4090
Vaishampayan U, Parchment RE, Jasti BR, et al
Taxanes: an overview of the phar-macokinetics and pharmacodynamics
Urology
1999;54(6A suppl):22-29
Van Moorsel CJA, Kroep JR, Pinedo HM, et al
Pharmacokinetic schedule finding study of the combination of gemcitabine and cisplatin in patients with solid tumors
Ann Oncol
1999;10:444-448
2007;60:759-766
Jolivet J
Role of leucovorin dosing and administration schedule
Eur J Cancer
1995;31A:1311-1315
Van Warmerdam LJ, Huizing MT, Giaccone G, et al
Clinical pharmacology of carboplatin administered in combination with paclitaxel
Semin Oncol
1997;24 (suppl 2):97-104
Joyce DA, Will RK, Hoffman DM, et al
Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid
Ann Rheum Dis
1991;50:913-914
Waltmire CN, Alberts DS, Dorr RT
Anticancer Drugs
2001;12:595-602
Juergens R, Brahmer J, Ettinger D
Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter
Cancer Chemother Pharmacol
2007;59:621-629
Sequence dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung
and ovarian cancer
Kano Y, Akutsu M, Tsunoda S, et al
Schedule-dependent synergism and antagonism between pemetrexed and paclitaxel in human carcinoma cell lines in vitro
Cancer Chemother Pharmacol
2004;54:505-513
Westermann AM, Taal BG, Swart M, et al
2000;42:151-156
Schedule-dependent synergism and antagonism between pemetrexed and docetaxel in human lung cancer cell lines in vitro
Cancer Chemother Pharmacol
2009;64:1129-1137
Sequence dependent toxicity profile in modified FAMTX (fluorouracil-adriamycin-methotrexate) chemotherapy
with lenograstim support for advanced gastric cancer: a feasibility study
Pharmacol Res
Kano Y, Tanaka M, Akutsu M, et al
Katsaros D, Oletti MV, Rigault de la Longrais IA, et al
Clinical and pharmaco-kinetic phase II study of pegylated liposomal doxorubicin and vinorelbine in heavily pretreated recurrent
ovarian carcinoma
Ann Oncol
2005;16:300-306
Yu NY, Patawaran MB, Chen JY, et al
Influence of treatment sequence on efficacy of fluorouracil and cisplatin intratumoral drug delivery in vivo
Cancer J Sci Am
1995;1:215-221
Zamboni WC, Egorin MJ, Van Echo DA, et al
Pharmacokinetic and pharmaco-dynamic study of the combination of docetaxel and topotecan in patients with solid tumors
JCO
2000;18:3288-3294
Sequence-dependent hematologic toxicity associated with the 3-hour paclitaxel/cyclophosphamide doublet
Clin Cancer Res
Zupi G, Scarsella M, D’Angelo C, et al
Potentiation of the antitumor activity of gemcitabine and paclitaxel in combination on human breast cancer cells
Cancer Biol Ther
2005;4:866-871
Kennedy MJ, Zahurak ML, Donehower RC, et al
1998;4:349-356
© October 2011 McKesson Specialty Health. All rights reserved.